About DARZALEX FASPRO®
DARZALEX FASPRO® is a prescription medicine used to treat adults with multiple myeloma.
What is DARZALEX FASPRO®?
DARZALEX FASPRO® is the subcutaneous (injected under the skin) formulation of daratumumab, used to treat:
- Newly diagnosed patients who can or cannot receive a transplant
- Patients who have had one or more other treatments for multiple myeloma
It is given by your healthcare provider under the skin in the stomach area (abdomen) and takes about 3 to 5 minutes
Prescribed alone or in combination with one or more treatments
See the Indications for DARZALEX FASPRO® below on this web page.
How DARZALEX FASPRO® works to fight multiple myeloma
DARZALEX FASPRO® is made up of 2 main components
Daratumumab (pronounced da-ra-tu-mu-mab)
Daratumumab is the ingredient that treats
multiple myeloma
Hyaluronidase (pronounced hy-a-lur-on-i-dase)
Hyaluronidase helps daratumumab to be injected into the skin and absorbed into the body
Daratumumab in action
Multiple myeloma cells, like other types of cancer, can go unrecognized by your body, which allows the cells to grow.
Daratumumab attaches itself to the CD38 protein on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.
Daratumumab directly kills multiple myeloma cells and/or allows your immune system to identify and destroy them. Because of the way daratumumab works, it may also affect normal cells.
Who is DARZALEX FASPRO® for?
Newly diagnosed
Transplant ineligible*
DRd: in combination with lenalidomide and dexamethasone
DVMP: in combination with bortezomib, melphalan, and prednisone
Transplant eligible*
DVTd: in combination with bortezomib, thalidomide, and dexamethasone
Previously treated
After ≥1 prior medicine
DRd: in combination with lenalidomide and dexamethasone
DVd: in combination with bortezomib and dexamethasone
DPd: in combination with pomalidomide and dexamethasone and previously treated with lenalidomide and a PI
After ≥3 prior medicines
Alone: previously treated with a PI and an immunomodulatory agent, or patients who did not respond to a PI and an immunomodulatory agent
*Transplant ineligible refers to when a person with multiple myeloma cannot receive a stem cell transplant, whereas transplant eligible means that a person with multiple myeloma can receive a stem cell transplant.
DRd=DARZALEX FASPRO® (D) + lenalidomide (R) + dexamethasone (d); DVd=DARZALEX FASPRO® (D) + bortezomib (V) + dexamethasone (d); DVMP=DARZALEX FASPRO® (D) + bortezomib (V) + melphalan (M) + prednisone (P); DVTd=DARZALEX FASPRO® (D) + bortezomib (V) + thalidomide (T) + dexamethasone (d); PI=proteasome inhibitor.